Tuesday, November 11, 2014

FDA Approves Ofev (nintedanib) for Idiopathic Pulmonary Fibrosis

In continuation of update on nintedanib

Nintedanib

The U.S. Food and Drug Administration today approved Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis is a condition in which the lungs become progressively scarred over time. As a result, patients with IPF experience shortness of breath, cough, and have difficulty participating in everyday physical activities. Current treatments for IPF include oxygen therapy, pulmonary rehabilitation, and lung transplant.

No comments: